In our data, focusing only on the CD40L+ 4-1BB+ Function+ CD4 T cells, or the 4-1BB+ Function+ CD8 T cells in the CRC/HD sample set would bring about the loss of approximately 72% and 27% of the identified Activation+ Function+ CD4 and CD8 T cells, respectively. The gene discussed is CD4; the disease is colorectal carcinoma.